Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E H Estey

Showing results (11-20 of 129) with videos related to

Pageof 13
Sort By:
Cancer|September 26, 2001
Therapeutic options for acute myelogenous leukemiaE H Estey
Annals of Hematology|May 6, 2004
New designs for phase II trials: application to a trial of targeted therapies vs. chemotherapy in patients age > 60 with AML/high-risk MDSE H Estey
Seminars in Hematology|April 1, 1995
Treatment of acute myelogenous leukemia and myelodysplastic syndromesE H Estey
Blood|April 15, 1994
Use of colony-stimulating factors in the treatment of acute myeloid leukemiaE H Estey
Best Practice & Research. Clinical Haematology|May 18, 2001
Growth factors in acute myeloid leukaemiaE H Estey
The New England Journal of Medicine|February 2, 1995
Post-remission chemotherapy for acute myeloid leukemiaE H Estey, M J Keating
Leukemia & Lymphoma|March 1, 1995
The contribution of Auer rods to the classification and prognosis of myelodysplastic syndromesJ F Seymour, E H Estey
Statistics in Medicine|July 15, 1993
A Bayesian strategy for screening cancer treatments prior to phase II clinical evaluationP F Thall, E H Estey
British Journal of Haematology|September 1, 1993
The prognostic significance of auer rods in myelodysplasiaJ F Seymour, E H Estey
Leukemia|July 10, 2014
Management of older or unfit patients with acute myeloid leukemiaR B Walter, E H Estey
Pageof 13

Showing results (11-20 of 129) with videos related to

Sort By:
Pageof 13
Cancer|September 26, 2001
Therapeutic options for acute myelogenous leukemiaE H Estey
Annals of Hematology|May 6, 2004
New designs for phase II trials: application to a trial of targeted therapies vs. chemotherapy in patients age > 60 with AML/high-risk MDSE H Estey
Seminars in Hematology|April 1, 1995
Treatment of acute myelogenous leukemia and myelodysplastic syndromesE H Estey
Blood|April 15, 1994
Use of colony-stimulating factors in the treatment of acute myeloid leukemiaE H Estey
Best Practice & Research. Clinical Haematology|May 18, 2001
Growth factors in acute myeloid leukaemiaE H Estey
The New England Journal of Medicine|February 2, 1995
Post-remission chemotherapy for acute myeloid leukemiaE H Estey, M J Keating
Leukemia & Lymphoma|March 1, 1995
The contribution of Auer rods to the classification and prognosis of myelodysplastic syndromesJ F Seymour, E H Estey
Statistics in Medicine|July 15, 1993
A Bayesian strategy for screening cancer treatments prior to phase II clinical evaluationP F Thall, E H Estey
British Journal of Haematology|September 1, 1993
The prognostic significance of auer rods in myelodysplasiaJ F Seymour, E H Estey
Leukemia|July 10, 2014
Management of older or unfit patients with acute myeloid leukemiaR B Walter, E H Estey
Pageof 13